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P-glycoprotein overexpression cannot explain the complete
doxorubicin-resistance phenotype in rat glioblastoma cell lines
S. Huet, B. Schott & J. Robert
Fondation Bergonie and Universite de Bordeaux II 180, rue de Saint-Genes - 33076 - Bordeaux Cedex, France.
Summary We have associated pharmacological studies to a semi-quantitative evaluation of P-glycoprotein(s)
expression, to establish if classical multidrug resistance (MDR) could account for the complete resistance
phenotype exhibited by progressively doxorubicin-resistant rat glioblastoma cells. Three resistant variants (C6
0.001, C6 0.1 and C6 0.5) of the C6 glioblastoma cell line (C6 S) were selected by long-term culture in the
presence of three concentrations of doxorubicin (0.001, 0.1 and 0.5psg.ml- respectively). The degree of
doxorubicin resistance was respectively 7, 33 and 400, and all the cell variants were cross-resistant to
m-AMSA, etoposide and vincristine. Doxorubicin incorporation was reduced similarly in all resistant cells,
irrespective of the level of resistance. When exposed to their respective doxorubicin IC50, the 7-fold resistant
cells had the same intracellular drug incorporation as the sensitive cells, whereas the 33-fold and 400-fold
resistant cells could incorporate respectively 3.7 and 17 times more drug. The ratio of doxorubicin exposures
required for 50% DNA synthesis inhibition and 50% growth inhibition was dependent on the degree of
resistance; this ratio was 12.8 in C6 S, 11.6 in C6 0.001, 6.3 in C6 0.1 and 1.8 in C6 0.5. P-glycoprotein(s)
overexpression was of the same magnitude as the resistance factor in variants C6 0.001 and C6 0.1, but was
lower than resistance factor in variant C6 0.5. Reversal ofdrug incorporation by verapamil was complete in all
resistant cell lines; however, reversal of doxorubicin cytotoxicity was complete only in the 7-fold resistant line
and was only partial in the most resistant lines, which remained 10-fold and 20-fold resistant to doxorubicin.
These results suggest that classical MDR was the first phenotype selected by doxorubicin in C6 0.001, whereas
mechanism(s) of doxorubicin resistance other than classical MDR are added in the most resistant lines.
Emergence ofmultidrug-resistant (MDR) tumour cells during
treatment is one of the major problems in cancer
chemotherapy. This resistance has been studied using drug-
resistant cell lines as an experimental model of this
phenomenon. Multidrug resistance is characterised by cross-
resistance to functionally and structurally unrelated drugs
(Skovsgaard, 1978) and by an impaired drug accumulation as
compared to the sensitive parental cell lines (Dano, 1973).
Concommitantly, overexpression of a high molecular weight
membrane glycoprotein (P-glycoprotein), encoded by the mdrl
gene, is usually observed with the emergence of multidrug
resistance (Juliano & Ling, 1976). Decreased drug retention
has been attributed mainly to enhanced active efflux of the
drug out of the cells, which is thought to occur via P-
glycoprotein (Gerlach et al., 1986) (see for review Bradley et
al., 1989; Endicott & Ling, 1989).
Multidrug-resistance can be reversed to various extents by
treatment of cells with the calcium channel blocker verapamil
(Tsuruo et al., 1981). It is now clear that verapamil exerts its
action by a mechanism that does not involve voltage-gated
calcium channels (Huet & Robert, 1988). However, the exact
mechanism of this effect is still unknown. The circumvention
of resistance is associated with increased drug accumulation,
probably through interaction of verapamil with the outward
drug transporter of resistant cells, P-glycoprotein. Data
demonstrating that verapamil inhibits the vinblastine
photoaffinity labelling of P-glycoprotein suggest that interac-
tion of this agent with P-glycoprotein could be the
biochemical basis for its pharmacological effects in MDR
cells (Cornwell et al., 1986). Moreover, using photoaffinity
analogs of verapamil, Safa (1988) has shown that P-
glycoprotein in MDR cells is a specific acceptor for
verapamil.
The relationship between drug incorporation and cytotox-
icity of anthracyclines has been extensively studied with
different approaches. In glioblastoma cells with high level of
resistance, we have shown that resistant cells can tolerate
higher amounts of drug than sensitive cells for a similar
cytotoxicity (Schott & Robert, 1989). It had been also
observed with this model that DNA synthesis inhibition
occurred for higher doses than growth inhibition only in
sensitive cells, suggesting that a distinct mechanism of cell
death occurred in sensitive and resistant cells. Such features
are not explained by the simple conception of P-glycoprotein
as the unique mechanism for multidrug resistance, and sug-
gest that additional mechanism(s) may lead to multidrug
resistance.
Alternative forms of multidrug resistance became apparent
in recent studies, especially a mechanism associated with
alterations of DNA-topoisomerase II. This particular resis-
tance was named by W.T. Beck 'atypical' MDR. In contrast
to 'classical' P-glycoprotein-mediated MDR, cells expressing
atypical MDR have no alteration in drug accumulation and
retention, and do not overexpress P-glycoprotein (Beck et al.,
1987; Morrow & Cowan, 1990).
Using pharmacological and molecular approaches, we
show in this paper that the mechanisms underlying resistance
were dependent on the degree of resistance in a model of
progressively doxorubicin-resistant rodent cells. Cells with
low level of resistance did not respond similarly to dox-
orubicin and verapamil as cells with high level of resistance.
Moreover, P-glycoprotein expression in these cell lines was
only slightly different despite their different levels of resis-
tance.
Materials and methods
Drugs and materials
Doxorubicin was a generous gift from Laboratoire Roger
Bellon. Verapamil was clinical formulation (Isoptinee). Media
and sera for cell culture originated from Seromed, Petri
dishes from Nunc.
[3H-methyl]thymidine was purchased from Amersham.
Liquid scintillation medium Pico-fluor was provided by
Packard.
C219 monoclonal antibody was purchased from Centocor
through CIS-International.
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Cell and culture conditions
The C6 clone originated from a brain tumour induced in rat
by N-methylnitrosourea. The resistant lines were obtained by
exposure of the sensitive cells (C6 S) to stepwise increasing
amounts of doxorubicin. Three levels of resistance: C6 0.001,
C6 0.1 and C6 0.5 were selected; they could be characterised
by the level of doxorubicin routinely tolerated by the cells in
the culture medium: 0.001 tg.ml-', 0.1 gIg.ml l1, 0.5 fLg.ml '
respectively. The cells were cultivated as monolayers in Petri
dishes with Dulbecco's modified Eagle medium supplemented
with 10% foetal calf serum and antibiotic mixture, at 37°, in
a humidified atmosphere containing 5% CO2. The cultures
were replicated each week and the medium was changed each
2 of 3 days, depending on the cell density.
Doxorubicin incorporation and [3H-methyl]thymidine
incorporation
For these evaluations, 8.104 C6 S cells or 10.104 C6 0.001
cells were seeded in 10 cm2 Petri dishes with 3 ml medium, or
25.104 C6 0.1 cells or 50.104 C6 0.5 cells were seeded in
20 cm2 Petri dishes with 5 ml of medium without drug. The
medium was changed 3 days later; on the fourth day, the
number of cells reached approximately 2.106 cells per dish in
all cases. Drug incorporation was measured by substituting
the medium by 3 ml new medium containing various concen-
trations of drug (0.032-320jg.ml- ) and the dishes were
incubated at 370 for 2 h. One hour before the end of the drug
exposure, 1 gCi of [3H-methyl]thymidine per dish was added.
Then, the monolayers were washed twice with 0.15 M NaCl,
harvested after gentle stirring and pelleted at 3,000 r.p.m. for
5 min. These steps were rapidly performed in order to avoid
any efflux of the drug; 0.5 ml of water and 0.5 ml of 40%
trichloracetic acid were successively added and the samples
were kept at 4°C overnight, then centrifuged for 30 min at
3,000 r.p.m. The acid-soluble fraction was used to evaluate
the intracellular concentration of non-covalently bound drug
by fluorometry (spectrofluorometer SFM25 Kontron) with
excitation and emission wavelengths set at 468 nm and
592 nm respectively. The acid-insoluble pellet was solubilised
with 1 M NaOH and used to evaluate both the protein
content (Lowry et al., 1951) and the 3H radioactivity in a
Beckman LS 1207 liquid scintillation spectrometer.
All incubations were performed in triplicate and three
independent experiments were performed. In all cases, incor-
poration of [3H-methyl]thymidine was referred to controls
realised in the same conditions and incubated without drug.
It was possible to define a TIC50 value, i.e. the concentration
of drug providing a 50% decrease of [3H-methyl]thymidine
incorporation.
MTT assay
A colorimetric assay utilising the tetrazolium salt, MTT, was
used to assess cytotoxicity of a 2 h exposure to doxorubicin
or other drugs in the presence or absence of verapamil. Cells
in log phase were harvested from flasks using trypsin-EDTA.
After resuspension in fresh medium, the cells were plated in a
volume of 200gsl at 5.102 cells per well for C6 S, 8.102 cells
per well for C6 0.001, 15.102 cells per well for C6 0.1, and
20.102 cells for C6 0.5. These cell densities were chosen
because they allowed exponential growth throughout a 5 day
period for C6 S and C6 0.001, and a 7 day period for C6 0.1
and C6 0.5. The plates were incubated at 37°C, in a
humidified atmosphere containing 5% C02, during 1 day for
C6 S and C6 0.001, and 2 days for C6 0.1 and C6 0.5
because their growth was slower. Then, culture medium was
replaced by fresh medium containing doxorubicin or other
drugs, and eventually verapamil, at the appropriate concen-
trations, and incubations were performed for 2h at 37°C.
After this drug exposure, monolayers were washed twice with
culture medium followed by addition of 300 jil of drug-free
medium per well. The plates were then incubated for 4 days
(C6 S cells and C6 0.001 cells) and 5 days (C6 0.1 and C6
0.5). Thereafter, 300 ftl of medium containing 0.5mg.mlh'
MTT were added in each well and the plate incubated at
37°C for additional 4h. Medium was then removed from
each well, 200,l of DMSO were added and the plate shaken
5 min; absorbance was immediately determined on a two-
wavelength microplate Auto reader (Biotek Instruments
EL311) at test and reference wavelengths of 570 nm and
630 nm respectively. The precision of this method using trip-
licate determination is 10% (s.d.). The cytotoxicity was ex-
pressed as the GIC50, i.e. the concentration of doxorubicin
causing 50% decrease of absorbance as compared to controls
incubated simultaneously without doxorubicin. Additional
blank controls consisting in the same growth medium and
drug conditions without cells were substracted from sample
absorbance values.
Doxorubicin efflux
Different concentrations of extracellular doxorubicin were
utilised in order to compensate for differences in cellular
accumulation of doxorubicin between the sensitive and resis-
tant sublines treated with or without verapamil. C6 S cells
were pretreated with 1 tig.ml-' doxorubicin in all conditions;
C6 0.001, C6 0.1 and C6 0.5 were pretreated with 10 ig.ml-'
doxorubicin without verapamil; in the presence of 3 ILM
verapamil, C6 0.001, C6 0.1 and C6 0.5 were pretreated with
1.3, 0.8 and 0.8 sgml-' doxorubicin respectively, and in the
presence of 30ylM verapamil, C6 0.001, C6 0.1, and C6 0.5
were pretreated with 0.76, 0.48 and 0.48Ag.ml-' doxorubicin
respectively. In these conditions, intracellular doxorubicin
concentration was approximately 120 ng/106 cells in all cases.
After 2 h at 37°C, incubation medium was removed and
monolayers were washed twice with NaCl 0.15 M and
immediately incubated in an equal volume of fresh drug-free
medium with or without verapamil at 37°C. At the prescribed
times, Petri dishes were removed and processed as indicated
for incorporation studies.
Western blot analysisfor P-glycoprotein
Cells in log phase were washed twice with PBS, harvested
from flasks by gentle stirring and pelleted at 1,500 r.p.m. for
5 min after counting. Cell pellets were washed with 40 mM
Tris and pelleted at 2,000 r.p.m. for 5 min at 4°C. Super-
natants were removed and replaced by 250jlI of 5 mM Tris,
6mM MgCl2, 1.5,l Aprotinin (32.2 TUI.ml-'). After 10 min
incubation, cells were homogenised by sonication. We have
checked with microscope that no intact cells remained. Then
were added 2501l 80 mM Tris, 6 mM MgCl2, 1.5ftl
Aprotinin, and 50yl DNaseI; the mixture was left at room
temperature for 30 min.
Protein measurement was done with Biorad reagent using
bovine serum albumin as a standard. The samples were then
frozen at -80°C.
Cell proteins, 800 gig to 200gIg per lane, were resolved by
SDS-PAGE using the method of Laemmli (1970). Protein
molecular weight standards were run in an adjacent lane, and
proteins were localised on nitrocellulose by Coomassie blue
staining. Proteins were transferred to nitrocellulose with an
electroblotting buffer system (Milliblot SDE Millipore) by the
method indicated by the manufacturer.
The blots were incubated 1 h at 37°C in blocking buffer
(0.9% NaCl, 10 mM Tris-HCI pH 7.5, 0.02% sodium azide,
5% dry milk, 3% IgG free BSA, and 0.2% Tween 20),
followed by incubation with C219 monoclonal antibody in
fresh blocking buffer at 4°C overnight. The filters were
washed with Tris-saline buffer, incubated with alkaline phos-
phatase-conjugated rabbit anti-mouse IgG in blocking buffer
at room temperature for 1.5 h, rewashed with Tris-saline
buffer and developed using BCIP substrate (0.5 mg.ml1')
(Blake et al., 1984).
Quantification was done by densitometric comparison of
the spots obtained; diluting the extracts from resistant cells
was done so as to obtain coloured spots of similar density as
those obtained with an extract from sensitive cells.540 S. HUETetal.
Results
Characteristics ofdoxorubicin-resistant cells compared to
doxorubicin-sensitive cells
Cross resistance patterns of the cell lines Multidrug resis-
tance character of the C6 variants used in this study was
evaluated by the measure of the cross-resistance between
doxorubicin (selecting agent), vincristine, m-AMSA and
etoposide (Table I). Resistance to doxorubicin was respec-
tively 7, 33 and 400 in the C6 0.001, C6 0.1 and C6 0.5
variants. Cross resistance to the other drugs of the classical
MDR profile was of the same order of magnitude as resis-
tance to doxorubicin in C6 0.001 cells and in C6 0.1 cells;
however, resistance to doxorubicin was much higher than
resistance to other drugs in C6 0.5 cells. Because of the
phase-dependence mechanism of action of vincristine, a 2 h
exposure could be too short to allow this drug to exert its
cytotoxicity; however, with exposures lasting for a complete
doubling time in C6 S and C6 0.5 cells, the resistance factor
of this line to vincristine was not higher than with a 2 h
exposure.
Doxorubicin-induced DNA synthesis inhibition The inhibition
of [3H]-thymidine incorporation (TICm) in C6 sublines is pre-
sented in Table II as IC50 of this parameter. It appears that
there was no correlation between GIC50 and TIC50 values,
neither in sensitive nor in resistant cells. Moreover, the ratio
of IC50 obtained for the two parameters was dependent on
the degree of resistance. The most resistant cells had the
lowest ratio TIC50/GIC50; thus, for C6 S, C6 0.001, C6 0.1
and C6 0.5, ratios were respectively 12.8, 11.6, 6.3 and 1.8.
Doxorubicin incorporation All doxorubicin-resistant cells
incorporated less drug than sensitive ones. However, the
decrease of doxorubicin incorporation was not correlated
with the degree of resistance since it was of the same mag-
nitude in all resistant sublines (Figure 1). Intracellular level
of doxorubicin required for 50% growth inhibition (GICm) in
C6 0.001 was identical to that of sensitive cells (Table II). In
contrast, in C6 0.1 and C6 0.5 cells, doxorubicin levels
exceeded those of the parent cell line, by 3.7 times and 17
times respectively.
It is worth noting that for 50% inhibition of DNA syn-
thesis C6 sensitive cells and C6 0.001 cells had incorporated
ten times more doxorubicin than for 50% growth inhibition,
and that this value markedly decreased in C6 0.1 and C6 0.5
cells.
Doxorubicin retention Doxorubicin efflux was more impor-
tant in resistant cells than in sensitive cells but was not
dependent on the degree of resistance. Indeed, doxorubicin
retention was identical in C6 0.1 cells and C6 0.5 cells, and
only slightly higher in C6 0.001 cells during the first hour of
efflux (Figure 2).
P-glycoprotein expression P-glycoprotein expression was
quantified by Western blotting using the C219 monoclonal
Table I Cross-resistance patterns of the C6 variant cell lines
GIC50 (gsM) Resistancefactor
Drug C6 S C6 0.001 C6 0.1 C6 0.5
m AMSA 0.32 1.3 12.6 25
Etoposide 2.29 2.8 11.7 29
Doxorubicin 0.15 6.7 33 400
Vincristine 3.40 5.9 37 50
The GIC5o ofthe drugs in C6 cells was determined by the MTT test
after a 2 h exposure to the drugs; resistance factor is the ratio of the
GICn obtained foreachdrugintheresistant variantand inthesensitive
line. Results are means of two independent experiments performed in
triplicate.
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Figure 1 Doxorubicin incorporation in sensitive and resistant C6
cells. Cells were exposed for 2 h to various concentrations of
doxorubicin, then washed and harvested for doxorubicin extrac-
tion and spectrofluorometric evaluation. Values are means of two
or three independent experiments performed in triplicate.
antibody, which recognises a very well-conserved epitope in
the C-terminal part of P-glycoprotein. The P-glycoprotein
detected in the sensitive line and the three resistant variants
had the same apparent molecular weight of 135 kDa (Figure
3a). Resistant variants contained more P-glycoprotein than
sensitive cells; this increase was proportional to resistance
factor in C6 0.001 and C6 0.1 lines which contained respec-
tively 10-25 and 50-75 times more P-glycoprotein than the
sensitive line; it was no longer related to resistance factor in
the C6 0.5 line which contained 75-100 times more P-
glycoprotein than the sensitive line (Figure 3b).
Reversal ofdoxorubicin resistance by verapamil
Effect of verapamil on doxorubicin incorporation The effect
of different concentrations of verapamil on doxorubicin
Table II Doxorubicin pharmacological effects on C6 variant cell lines differing in their degree of resistance to doxorubicin
Doxorubicin-induced growth inhibition Doxorubicin-induced DNA synthesis inhibition
Doxorubicin Doxorubicin
incorporation incorporation
Resistance GIC50 at GIC50 TIC50 at TIC50 TIC50/
Cell line factor jsg.ml-tI lg Dox/106 cells fig.mlh figDox/106 cells GIC50
C6 S 1 0.090 0.017 1.15 0.170 12.8
C6 0.001 7 0.600 0.014 6.93 0.120 11.6
C6 0.1 33 2.95 0.063 18.5 0.225 6.3
C60.5 400 36.4 0.288 66 0.552 1.8
Cytotoxicity was expressed as GIC50, i.e. the concentration ofdrug reducing cell number by 50% after a 2 h exposure to the
drug; DNA synthesis inhibition was expressed as TIC50, i.e. the concentration ofdrug reducing by 50% the amount oftritiated
thymidine incorporated in DNA after a 2 h exposure to the drug. Values are means of three independent experiments, each
performed in triplicate. Doxorubicin incorporation at GIC50 andTICn0 were determined by interpolation on the curve plotting
doxorubicin incorporation vs drug exposure dose.
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Figure 2 Cellular retention of doxorubicin in sensitive and resis-
tant C6 cells. Cells were exposed for 2 h to doxorubicin doses
leading to a similar drug intracellular concentration of 120 ng/10.6
cells in all cell lines: 1 ig ml-' for C6 S cells and 10 g.ml-I for
C6 0.001, C6 0.1 and C6 0.5 cells. Medium was then removed
and replaced by doxorubicin-free medium for various periods as
indicated cells were then harvested for doxorubicin extraction and
spectrofluorometric evaluation. Values are means of two or three
independent experiments performed in duplicate. - x - C6 S; -0-
C6 0.001; -0- C6 0.1; -A- C6 0.5.
accumulation was studied after 2 h of incubation, when dox-
orubicin concentration steady state was reached (Figure 4).
Doxorubicin accumulation was dependent upon verapamil
concentration between 0.1 and 1O tM in all doxorubicin-
resistant sublines examined; beyond 10 gM of verapamil, dox-
orubicin accumulation did not further increase. Doxorubicin
accumulation was unchanged in C6 sensitive cells. In all
resistant sublines I .tM of verapamil significantly increased
doxorubicin incorporation, and 3 gM completely restored the
incorporation to the level obtained in the sensitive line. In C6
0.1 and C6 0.5 cells, doxorubicin incorporation in the
presence of 10 or 50 jaM ofverapamil was even higher than in
C6 sensitive cells (Figure 4).
Effect of verapamil on doxorubicin-induced growth inhibi-
tion The effect of various concentrations of verapamil on
doxorubicin cytotoxicity was evaluated by incubating the
cells with graded concentrations of doxorubicin for 2 h
(Table III). Verapamil itself was non-cytotoxic to sensitive
and doxorubicin-resistant sublines at the extracellular con-
centrations and exposure times used. For increasing
verapamil concentrations up to 3 SAM, doxorubicin cytotox-
icity was progressively enhanced in all cell lines. Beyond 3 AM
of verapamil, GIC50 was stable and reached a stable minimal
value, dependent on the resistance level of the cell line. This
GIC50 was similar in the C6 S and in the C6 0.001 lines; it
was accompanied by similar intracellular accumulation of
doxorubicin (Table IV). In contrast, in C6 0.1 and C6 0.5 cell
lines, the stable GICso values remained much higher than in
the sensitive line, although the reversal of drug accumulation
at a fixed dose was complete. Doxorubicin incorporations
corresponding to these ICs remained in the same range of
values as without verapamil (Table IV).
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Figure 3 Western blots of electrophoretic profiles of C6 sensitive
and resistant cells as revealed with C219 antibody. a, 400 jAg of
whole cell lysate proteins were laid down for each line, excepted
in the first lane (800jg). b, Dilutions of whole cell lysate proteins
were laid down as indicated for each cell line.
creased in the presence of 3 gM of verapamil in all resistant
cell lines (Figure 5a), but verapamil effect was more impor-
tant in C6 0.001 than in C6 0.1 and C6 0.5, so that dox-
orubicin efflux in C6 0.001 cells was of the same magnitude
as in C6 S cells. At a concentration of 30 giM of verapamil
(Figure Sb) doxorubicin efflux was completely inhibited in all
cell lines.
Effect of verapamil on doxorubicin-induced DNA synthesis
inhibition Verapamil effect on inhibition of 3H-thymidine
incorporation in C6 sensitive and resistant variants is pre-
sented in Table III, as IC50 of this parameter. It appears that
verapamil effect on DNA synthesis inhibition induced by
doxorubicin was similar to that observed on growth, so that
TIC50/GIC50 ratio was the same in all cell lines, whatever
verapamil concentration.
Effect of verapamil on doxorubicin retention Doxorubicin
retention was studied in all cell lines in the presence of 3 and
30 jiM of verapamil. Drug retention was significantly in-
Discussion
In this set of doxorubicin-resistant variants originating from
the same cell line, no correlation existed between the degree
of resistance and the net accumulation of doxorubicin. At the
same drug exposure, all resistant cell lines exhibited the same
reduction of drug accumulation. Moreover, the increase of
drug efflux was of the same level in all resistant variants. This
reduction of drug accumulation may explain by itself the
degree of resistance of the C6 0.001 line (7-fold) but not the
33-fold and 400-fold reistance factors observed in the C6 0.1
and C6 0.5 lines respectively. Equivalent lack of correlation
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doxorubicin-resistant sublines of L12
al. (1989) in pancreatic cancer cell lii
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resistance.
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much doxorubicin as sensitive cells, N
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doxorubicin than sensitive cells.
doxorubicin-resistant cells to higher
than sensitive cells has already been
authors (Chang et al.,1989; Kessel &
therefore likely that mechanism(s) other than doxorubicin
efflux must be operating in the most resistant cells and the
purpose of this work was to bring further evidence to this
assumption.
In the C6 0.001 and C6 0.1 lines, the cross-resistance
pattern was the one classically observed in multidrug resis-
tant cells, with a slightly higher resistance to the selecting
agent (doxorubicin) than to the other drugs; in the C6 0.5
line however, the resistance to doxorubicin further increases
12 times when compared to the C6 0.1 line, whereas resis-
tance to the other agents was only twice higher. This is in
agreement with the emergence in this line of supplementary
doxorubicin-specific mechanism of resistance.
Another primary observation was the fact that DNA syn-
a IV UV thesis inhibition was obtained for much higher doxorubicin
(±M) exposures than growth inhibition in C6 S and C6 0.001 cells,
whereas doxorubicin doses required for DNA synthesis
orubicin incorporation in inhibition and growth inhibition were much closer in C6 0.5
were exposed for 2 h to cells, as already pointed out by us (Schott & Robert, 1989).
icentrations of verapamil This can be interpreted as a difference in the mechanism of
,o or three independent cytotoxicity in sensitive and highly resistant cells, this
mechanism being the same in sensitive and slightly resistant
cells. During the increment of doxorubicin resistance, new
mechanism(s) of resistance appear, leading to new targets of
doxorubicin cytotoxicity in highly resistant cell lines. Baas et
Grabowski (1988) in al. (1990) recently provided evidence that, in contrast, non
!10 mouse, by Chang et P-glycoprotein-mediated mechanisms for MDR preceded the
nes and leukaemia, and classical occurrence of P-glycoprotein expression during in
s. In contrast, Keizer et vitro selection of doxorubicin resistant variants of a human
resistant variants of the lung cancer cell line.
e SW1573, a correlation We have shown that C6 0.1 cells contained significantly
ke level of doxorubicin more P-glycoprotein than C6 0.001 cells, which could explain
the higher resistance of these cells to doxorubicin; however,
ilarly cytotoxic dose of C6 0.5 cells contain nearly the same amount of P-glyco-
tant cells incorporate as protein as C6 0.1 cells despite an increase of 12-fold in
whereas the 33-fold and resistance. There again, the molecular approach leads to the
3.7 and 17 times more same conclusion as the pharmacological one. In the same
This tolerance of way, the results of Mukhopadhyay and Kuo (1989) have
intracellular drug levels shown an increment of P-glycoprotein production only in the
pointed out by several low-level vincristine-resistant CHO cells, and no additional
Wilberding, 1985). It is overproduction in the cells with higher levels of drug resis-
Table III Effect ofverapamil ondoxorubicin-induced growth inhibition and DNA synthesis inhibition in wild and resistant variants ofthe C6
cell line
Doxorubicin-inducedgrowth Doxorubicin-induced DNA
Verapamil inhibition GIC50 synthesis inhibition TIC50 TIC50
concentration (sg.ml') (1og.ml') G1C50
(tAM) C6S C6 0.001 C6 0.1 C6 0.5 C6 S C6 0.001 C6 0.1 C6 0.5 C6 S C6 0.001 C6 0.1 C6 0.5
0 0.090 0.600 2.95 36.4 1.15 6.93 18.5 66 12 12 6.3 1.8
0.1 - 0.345 1.88 22.6 - 4.60 12.5 46 - 13 6.6 2.0
1 0.057 0.086 0.59 2.25 - 0.84 2.90 8.30 - 10 4.9 3.7
3 - 0.063 0.275 1.71 - 0.84 2.08 2.68 - 13 7.6 1.6
10 0.055 0.062 0.345 1.52 - 0.70 2.05 2.20 - 12 6.0 1.4
30 0.063 0.066 0.280 1.95 - - - 1.80 - - - 0.9
GIC50 and TIC50 were defined in Table II. They were determined in the presence ofvarious concentrations ofverapamil, from 0.1 to 30 jAM.
Values are means of two or three independent experiments performed in triplicate.
Table IV Effects ofverapamil on doxorubicin incorporation atGIC50 and TIC50inwild and resistant
variants of the C6 cell lines
Verapamil Doxorubicin incorporation Doxorubicin incorporation
concentration at GIC50 (j.g/106 cells) at TIC50 (lig/JO6 cells)
(AM) C6 S C6 0.001 C6 0.1 C6 0.5 C6 S C6 0.001 C6 0.1 C6 0.5
0 0.017 0.014 0.063 0.288 0.170 0.120 0.225 0.552
0.1 - 0.009 0.045 0.265 - 0.089 0.195 0.483
1 0.014 0.009 0.063 0.138 - 0.077 0.210 0.391
3 - 0.011 0.053 0.288 - 0.113 0.270 0.437
10 0.014 0.011 0.083 0.311 - 0.110 0.420 0.449
30 0.015 0.011 0.075 0.495 - - - 0.460
Drug incorporation at GIC50 and TIC50 were determined by interpolation on the curve plotting
doxorubicin incorporation vs exposure dose. Values are means of three independent experiments.
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Figure 5 Cellular retention of doxorubicin in the presence of
verapamil. a, cells were exposed for 2 h to 3t4m of verapamil and
specific doxorubicin doses leading to a similar drug intracellular
concentration in all cell lines:1 j.g.ml1' for C6 S cells,
1.3fig.ml ' for C6 0.001 cells, 0.8gLg.ml for C6 0.1 and C6 0.5
cells. b, cells were exposed for 2 h to 30 jAm of verapamil and
specific doxorubicin doses leading to similar drug intracellular
concentrations in all cell lines: 1 tLg ml-' for C6 5; 0.76tLg ml-'
for C6 0.001 cells; 0.48tg ml-' for C6 0.1 and C6 0.5 cells. In
both cases, medium was removed at the end of the incubation
and replaced with doxorubicin-free medium for various periods
as indicated. Cells were then harvested for doxorubicin extraction
and spectrofluorometric evaluation. Values are means of two
independent experiments performed in duplicate. - x - C6 S; -0-
C6 0.001; -0- C6 0.1; -A- C6 0.5.
tance. Moreover, these authors have observed that phos-
phorylation and glycosylation of P-glycoprotein could not
account for the difference in levels of drug resistance in these
MDR cells. Keizer et al. (1989) found a positive correlation
between P-glycoprotein expression and the level of dox-
orubicin resistance; however, for resistance factors in the
range 10-250, they observed that P-glycoprotein expression
was not significantly different.
Verapamil reversal of doxorubicin resistance and incor-
poration provided new insights on the questions raised. This
drug had a dose-dependent effect up to 3IM, but the effect
of this modulator reaches then a plateau, beyond which no
further reduction of GIC50 was obtained. Thus, it appears
that 1 tiM of verapamil completely reversed multidrug resis-
tance in C6 0.001, but partially reversed multidrug resistance
in C6 0.1 and C6 0.5; the reversal remained partial even with
the highest concentration of verapamil, which could however
restore drug incorporation at the same level as in sensitive
cells, and completely suppress doxorubicin efflux. Similar
results had been observed with human ovarian cancer cells
(Rogan et al., 1984). It is worth to note that, in each cell line,
DNA synthesis inhibition paralleled growth inhibition, so
that the ratio TICjo/GICm was constant in each resistant
variant, whatever the concentration of verapamil. This obser-
vation is in favour of a limitation of the role of verapamil to
the regulation of intracellular drug concentration, without
any effect on the intracellular targets of doxorubicin. Recent
works showing the inhibition of anticancer drug binding to
P-glycoprotein by verapamil agree with this conception of
verapamil effect (Cornwell et al., 1986; Safa, 1988).
Both pharmacological and molecular arguments led us to
the conclusion that complementary mechanism(s) other than
P-glycoprotein-mediated drug efflux are operating in C6 0.5
cells, and probably also to a lesser extent in C6 0.1 cells,
whereas C6 0.001 cells appear as 'pure' P-glycoprotein-
mediated multidrug resistant cells. Schuurhuis et al. (1989)
have shown that a high enough concentration of verapamil
(32 ELM) could completely reverse the resistance of colchicine-
resistant Chinese hamster ovary cells which were 350-fold
doxorubicin resistant; the authors show that verapamil was
able to shift doxorubicin from cytoplasm to nucleus, which
explains a verapamil-induced reduction of doxorubicin incor-
poration at a given cytotoxicity. With our cells, we never
observed such a verapamil-induced reduction of doxorubicin
incorporation at IC50 exposure; the elegant demonstration of
these authors, that the complete doxorubicin-resistant pattern
of their cells was explained by an enhancement of active drug
efflux and a change in intracellular doxorubicin distribution,
is therefore not valid in our cells.
Several 'multifactorial' doxorubicin-resistant lines have
already been obtained. A P-glycoprotein-independent mech-
anism of resistance to doxorubicin and other natural prod-
ucts has recently been described (Danks et al., 1988) and
assigned to alteration of DNA-topoisomerase II; it was called
at-MDR by contrast to P-glycoprotein-mediated MDR (P-gp
MDR). Other mechanisms of resistance to doxorubicin have
been postulated without definitive demonstration; they often
involve the role of glutathione-related enzymes and imply an
enhanced detoxication ofdrugs or of products of drug action
(Mitchell, 1988; Singh et al., 1989).
It has not often been considered that several mechanisms
could be operating together in the same cell line. Our
experiments bring some evidence that P-glycoprotein,
although overexpressed in all resistant variants, can explain
by itself the resistance of the least resistant C6 line, but
cannot be sufficient to account for the resistance phenotype
of our most resistant variants. We are now identifying the
mechanisms complementary to 'classical' MDR which could
explain these complex phenotypes.
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blotting technique. This paper was supported by grants from
INSERM (CRE 90.0208), from ARC, from the Ligue Nationale
Franqaise contre le Cancer and from GEFLUC.
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and to Ms F. Turbak for typing the manuscript.
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